Nectar Lifesciences informs about disclosures

11 Jun 2025 Evaluate

With reference to point no. 2 of Annexure 1 of letter nos. NLL/CS/2024-438 dated November 22, 2024, and NLL/CS/2024-476 dated April 04, 2025, vide which the Company had informed pending Litigation(s) as required under Regulation 30 of the LODR Regulations. Pursuant to : Regulation 30 of the Securities and Exchange of Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and as amended by Circular dated March 28, 2025, Nectar Lifesciences has informed that it enclosed necessary disclosures in prescribed format for details/ updation of Litigation and/ or orders passed by any regulatory authority or judicial body as per Annexure-A.

The above information is a part of company’s filings submitted to BSE.

Nectar Lifesciences Share Price

14.58 0.69 (4.97%)
22-Jan-2026 14:12 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1614.10
Dr. Reddys Lab 1217.50
Cipla 1371.95
Zydus Lifesciences 884.95
Lupin 2161.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×